Renbioscience
1 employees on LinkedIn · 1 known investors
Ren BioScience develops small-molecule therapies aimed at preserving organ function, including an oral lead compound for inherited retinal diseases and preclinical programs targeting acute kidney injury and mitochondrial-driven metabolic and autoimmune conditions. Its focus is on protecting cells from irreversible injury across ophthalmic, renal, and metabolic disease areas.
Founders & leadership
RS
Ray StevensinChief Executive Officer
DB
Dale BennyhoffChief Operating Officer
DS
Dr. Stewart McCallumChief Medical Officer
Investors · 1
Competitors · 3
by search overlapDren Bio6 shared keywordsDren Bio is a clinical-stage biopharmaceutical company developing novel antibody therapeutics designed to selectively eliminate pathogenic cells and disease-causing agents, with a pipeline targeting oncology, autoimmune diseases, immunology, and neurology.
RenBio6 shared keywordsRenBio develops DNA-based therapeutic technology that uses intramuscular injection of therapeutic-encoding "bioblueprints" so a patient's own muscle cells produce antibodies and therapeutic proteins to prevent and treat diseases, including infectious diseases. The company works in the antibody and therapeutic protein field, aiming to overcome obstacles in delivery, durability, and cost.
NeoGenomics3 shared keywordsNeoGenomics provides oncology diagnostics and laboratory testing, offering over 500 tests across modalities including molecular testing, IHC, flow cytometry, FISH, next-generation sequencing, and comprehensive genomic profiling for solid tumors and hematologic cancers. It serves oncologists, patients, and biopharma partners in the US, supporting clinical care as well as drug development and clinical trials.
Companies competing with Renbioscience for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Renbioscience do?
- Ren BioScience develops small-molecule therapies aimed at preserving organ function, including an oral lead compound for inherited retinal diseases and preclinical programs targeting acute kidney injury and mitochondrial-driven metabolic and autoimmune conditions. Its focus is on protecting cells from irreversible injury across ophthalmic, renal, and metabolic disease areas.
- Who are Renbioscience's investors?
- Renbioscience's investors include The Innovation Space.